Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 9/20 | 0.76 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | BRAF | P15056 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | RAF1 | P04049 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.65 |
| ▸ | KCNK9 | Q9NPC2 | 4/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7606555 | 0.93 | KCNK3 (0.68) | KCNK3MAPK14ALDH1A1MAPTBRAF | |
| SCHEMBL15599473 | 0.89 | MAPK14 (0.76) | KCNK3MAPK14ALDH1A1MAPTBRAF | |
| SCHEMBL12763862 | 0.89 | KCNK3 (0.75) | KCNK3MAPK14ALDH1A1MAPTBRAF | |
| SCHEMBL10028403 | 0.87 | MAPK14 (0.85) | KCNK3MAPK14ALDH1A1MAPTBRAF | |
| SCHEMBL12764313 | 0.86 | KCNK3 (0.80) | KCNK3MAPTTP53CYP1A2CYP3A4 | |
| SCHEMBL12228168 | 0.85 | RAB9A (0.71) | KCNK3ALDH1A1MAPTTP53CYP1A2 | |
| SCHEMBL8970557 | 0.84 | KCNK3 (0.70) | KCNK3MAPK14ALDH1A1MAPTBRAF | |
| SCHEMBL7745692 | 0.84 | KCNK3 (0.80) | KCNK3ALDH1A1MAPTTP53HPGD | |
| SCHEMBL6782639 | 0.82 | BTK (0.64) | KCNK3MAPK14ALDH1A1MAPTBRAF | |
| SCHEMBL15482247 | 0.82 | HDAC6 (0.63) | KCNK3MAPK14ALDH1A1MAPTBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180214449-A1 | CANCER THERAPY USING JAK INHIBITOR IN COMBINATION WITH MAPK INHIBITORS | UBRX, INC. | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214449-A1 | CANCER THERAPY USING JAK INHIBITOR IN COMBINATION WITH MAPK INHIBITORS | JAK2, JAK1, JAK3 | KCNK3 3813/4885MAPK14 37/4885ALDH1A1 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.